296 related articles for article (PubMed ID: 20226194)
21. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
22. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
[TBL] [Abstract][Full Text] [Related]
23. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.
Lundberg E; Höidén-Guthenberg I; Larsson B; Uhlén M; Gräslund T
J Immunol Methods; 2007 Jan; 319(1-2):53-63. PubMed ID: 17196217
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
[TBL] [Abstract][Full Text] [Related]
25. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
26. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides.
Grönwall C; Jonsson A; Lindström S; Gunneriusson E; Ståhl S; Herne N
J Biotechnol; 2007 Jan; 128(1):162-83. PubMed ID: 17088007
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
[TBL] [Abstract][Full Text] [Related]
28. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
[TBL] [Abstract][Full Text] [Related]
29. High-affinity binding to staphylococcal protein A by an engineered dimeric Affibody molecule.
Lindborg M; Dubnovitsky A; Olesen K; Björkman T; Abrahmsén L; Feldwisch J; Härd T
Protein Eng Des Sel; 2013 Oct; 26(10):635-44. PubMed ID: 23924760
[TBL] [Abstract][Full Text] [Related]
30. Anti-idiotypic protein domains selected from protein A-based affibody libraries.
Eklund M; Axelsson L; Uhlén M; Nygren PA
Proteins; 2002 Aug; 48(3):454-62. PubMed ID: 12112671
[TBL] [Abstract][Full Text] [Related]
31. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
[TBL] [Abstract][Full Text] [Related]
32. Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay.
Löfdahl PA; Nord O; Janzon L; Nygren PA
N Biotechnol; 2009 Nov; 26(5):251-9. PubMed ID: 19576305
[TBL] [Abstract][Full Text] [Related]
33. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
Fortin MA; Orlova A; Malmström PU; Tolmachev V
Int J Mol Med; 2007 Feb; 19(2):285-91. PubMed ID: 17203203
[TBL] [Abstract][Full Text] [Related]
34. Engineered affinity proteins for tumour-targeting applications.
Friedman M; Ståhl S
Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
[TBL] [Abstract][Full Text] [Related]
35. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
36. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
Tolmachev V; Nilsson FY; Widström C; Andersson K; Rosik D; Gedda L; Wennborg A; Orlova A
J Nucl Med; 2006 May; 47(5):846-53. PubMed ID: 16644755
[TBL] [Abstract][Full Text] [Related]
37. Selection and characterization of HER2/neu-binding affibody ligands.
Wikman M; Steffen AC; Gunneriusson E; Tolmachev V; Adams GP; Carlsson J; Ståhl S
Protein Eng Des Sel; 2004 May; 17(5):455-62. PubMed ID: 15208403
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
[TBL] [Abstract][Full Text] [Related]
39. Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold.
Juraja SM; Mulhern TD; Hudson PJ; Hattarki MK; Carmichael JA; Nuttall SD
Protein Eng Des Sel; 2006 May; 19(5):231-44. PubMed ID: 16549402
[TBL] [Abstract][Full Text] [Related]
40. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
Löfblom J; Feldwisch J; Tolmachev V; Carlsson J; Ståhl S; Frejd FY
FEBS Lett; 2010 Jun; 584(12):2670-80. PubMed ID: 20388508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
